A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.

Jayesh DesaiPeter FongVictor MorenoSophia FrentzasTarek MeniawyBen MarkmanMark VoskoboynikTahmina RahmanNageshwar BudhaJohn WuJin MarlowSilu YangEmiliano CalvoJuan Martin-Liberal

Published in: British journal of cancer (2023)

NCT03379259.

Keyphrases

open label
double blind
placebo controlled